Tempus AI

In a recent Q&A, Dr. Michelle Ting-Lin, Medical Director of Clinical Development at Tempus, provides insights into the science behind the Immune Profile Score (IPS), a novel biomarker designed to enhance the identification of patients who may benefit from immune checkpoint inhibitor (ICI) therapies. Read here: https://tempus.co/4i9EftN

We're looking forward to participating in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, in New York. Our CEO and founder Eric Lefkofsky will participate in a fireside discussion on December 3 at 3:00 p.m. ET. Learn more: https://tempus.co/4eMkm9a

Join us for an upcoming webinar, “Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies” on December 5 at 12 PM CT. Hear from Calvin Chao, MD, Timothy J. Taxter, M.D., and Natalie Vokes, MD, on the role novel biomarkers and combination treatment strategies play in understanding and enhancing the immune system's response to cancer. Register here: https://tempus.co/4fxjfeS

A recent case study illustrates Tempus Next’s ability to help close the biomarker testing gap for early stage #NSCLC. Tempus Next was deployed to help TriHealth Cancer and Blood Institute achieve 100% compliance with targeted biomarker testing guidelines for resectable stage IB-III NSCLC. Read the full case study here: https://tempus.co/3OjwfsE

We’re thrilled to?announce?this collaboration with Medtronic,?which utilizes the Tempus Next platform to identify causes of undertreatment of minority patient groups with severe aortic stenosis, moderate to severe and severe mitral regurgitation for recommended therapies. By harnessing the power of AI, Tempus Next identifies care gaps and equips clinicians with actionable insights at the point of care.

We are now offering germline RNA analysis as part of our comprehensive genetic testing portfolio. +RNAinsight? (powered by Ambry Genetics) analyzes RNA to support the classification and detection of DNA variants, including those that may be missed by DNA-only assays. It is now available as an add-on test for xG (CancerNext?) and xG+. Learn more: https://tempus.co/3UYrrg0

Reminder to join us for this week's webinar, “Precision outcomes research: Shaping the future of oncology biopharma with real-world evidence” on November 21 at 12 PM CT. Moderator Emilie Scherrer will be speaking with Vadim Koshkin, MD, Mark Stewart, PhD, and Somnath Sarkar, MD, to explore how leveraging outcomes data drives innovation and improves patient outcomes across the continuum of care. Register here: https://tempus.co/3UBKEE7

Immunotherapy is transforming cancer care, but identifying the right patients for these treatments remains a challenge. We are leading the way in immuno-oncology with our Immune Profile Score (IPS), a first-of-its-kind biomarker utilizing DNA and RNA to prognosticate immune checkpoint inhibitor (ICI) response. By addressing the complexities of biomarker identification in research, IPS can help overcome these challenges in an effort to improve patient outcomes. IPS is just one of the many solutions available through Tempus IO, our comprehensive platform designed to support your research with comprehensive real-world data, a robust suite of IO biomarkers, and advanced analytical technology. Learn more: https://tempus.co/3Cv7QO8

In a recent Q+A, our Chief Scientific Officer, Kate Sasser, PhD, expands on how Tempus is utilizing real-world data for novel target discovery, clinical trial optimization, translational research, and evidence generation. Read here: https://tempus.co/4g7u7QL

We are so thankful for the genetic counselors at Tempus who are essential in bridging the gap between advanced genomic testing and personalized patient care. Join us in celebrating #GeneticCounselorAwarenessDay and the passion these dedicated team members bring to Tempus each day.